Ashley Eldridge
Maine Medical Center
12 Papers
4 Citations
Ashley Eldridge is an academic researcher from Maine Medical Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 8 publications.
Chat about Author
Papers
Neurological Pupil Index and Pupillary Light Reflex by Pupillometry Predict Outcome Early After Cardiac Arrest
Richard R. Riker,Mary Sawyer,Victoria Fischman,Teresa May,Christine Lord,Ashley Eldridge,David B. Seder +6 more
TL;DR: Very early after resuscitation from cardiac arrest, abnormal Neurological Pupil index and pupillary light reflex measurements by pupillometer are predictive of poor outcome, and are not usually associated with dilated pupils.
92
Amantadine and Modafinil as Neurostimulants During Post-stroke Care: A Systematic Review
David R. Gagnon,Angela M. Leclerc,Richard R. Riker,Caitlin S. Brown,Teresa May,Kristina Nocella,Jennifer Cote,Ashley Eldridge,David B. Seder +8 more
TL;DR: Amantadine and modafinil may improve cognitive and functional recovery post-stroke, but higher-quality data are needed to confirm this conclusion, especially in the acute care setting.
36
Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial
David J. Gagnon,Sergey Ryzhov,Meghan May,Richard R. Riker,Bram J. Geller,Teresa May,Sarah Bockian,Joanne T. deKay,Ashley Eldridge,Thomas E. Van der Kloot,Patricia Lerwick,Christopher P. Lord,F. Lee Lucas,Patrick Mailloux,Barbara McCrum,Meghan P. Searight,Joel A. Wirth,Jonathan B. Zuckerman,Douglas B. Sawyer,David B. Seder +19 more
TL;DR: The PROTECT trial as mentioned in this paper is a randomized, placebo-controlled, single-center, quadruple-blind (patient, treatment team, research team, outcome assessors), non-commercial, superiority trial to be conducted at Maine Medical Center in Portland, Maine, USA.
Community consultation for Exception from Informed consent (EFIC) before and during the COVID-19 pandemic
David J. Gagnon,Richard R. Riker,F Chessa,Christopher P. Lord,Ashley Eldridge,Meghan P. Searight,Sarah Bockian,Barbara McCrum,Teresa May,Douglas B. Sawyer,David B. Seder +10 more
TL;DR: The PEARL trial as discussed by the authors randomized OOHCA patients without ST-elevation to early cardiac catheterization or not to prophylactic ceftriaxone or placebo, with an acceptance rate of 92 % for the community and 76 % for personal level.
3
Decreased circulating CD73 and adenosine deaminase are associated with disease severity in hospitalized patients with COVID-19
Jonathan Rud,Richard R. Riker,Ashley Eldridge,Christopher P. Lord,Joanne T. deKay,Teresa May,David J. Gagnon,Douglas B. Sawyer,Sergey Ryzhov,David B. Seder +9 more
TL;DR: In this paper , the levels of soluble CD73 and soluble Adenosine Deaminase (ADA) in hospitalized patients with COVID-19 and determine if levels of these molecules are associated with disease severity.
2